Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
Authors
Keywords
-
Journal
CURRENT MEDICAL RESEARCH AND OPINION
Volume 38, Issue 5, Pages 731-742
Publisher
Informa UK Limited
Online
2022-04-08
DOI
10.1080/03007995.2022.2059975
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
- (2020) Messoud Ashina et al. CEPHALALGIA
- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
- (2020) Stewart J Tepper et al. CEPHALALGIA
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY
- (2020) Peter J. Goadsby et al. NEUROLOGY
- Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
- (2020) Janet Ford et al. QUALITY OF LIFE RESEARCH
- Consensus of the Brazilian Headache Society on the treatment of chronic migraine
- (2019) Fernando KOWACS et al. ARQUIVOS DE NEURO-PSIQUIATRIA
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine
- (2018) Uwe Reuter HEADACHE
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
- (2018) Angelo Camporeale et al. BMC Neurology
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of calcitonin gene–related peptide in peripheral and central pain mechanisms including migraine
- (2017) Smriti Iyengar et al. PAIN
- Pathophysiology of Migraine: A Disorder of Sensory Processing
- (2017) Peter J. Goadsby et al. PHYSIOLOGICAL REVIEWS
- Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
- (2016) Zsolt Hepp et al. CEPHALALGIA
- Systematic Review of Migraine Prophylaxis Adherence and Persistence
- (2016) Zsolt Hepp et al. JOURNAL OF MANAGED CARE PHARMACY
- Adherence to oral migraine-preventive medications among patients with chronic migraine
- (2014) Zsolt Hepp et al. CEPHALALGIA
- Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain
- (2014) R.J. Benschop et al. OSTEOARTHRITIS AND CARTILAGE
- The International Classification of Headache Disorders, 3rd edition (beta version)
- (2013) CEPHALALGIA
- Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
- (2013) Andrew M. Blumenfeld et al. HEADACHE
- Analysis of the duration of migraine prophylaxis
- (2013) Raimundo Pereira Silva-Néto et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Is 6 months of migraine prophylaxis adequate?
- (2013) Sanjeev K Bhoi et al. NEUROLOGICAL RESEARCH
- Chronic Migraine Prevalence, Disability, and Sociodemographic Factors: Results From the American Migraine Prevalence and Prevention Study
- (2012) Dawn C. Buse et al. HEADACHE
- Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1
- (2012) S.D. Silberstein et al. NEUROLOGY
- Adherence with Migraine Prophylaxis in Clinical Practice
- (2012) Ariel Berger et al. Pain Practice
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now